Cigna Investments Inc. New raised its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 21.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,150 shares of the biopharmaceutical company’s stock after buying an additional 1,936 shares during the period. Cigna Investments Inc. New’s holdings in Alexion Pharmaceuticals were worth $1,357,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in ALXN. Candriam Luxembourg S.C.A. raised its position in shares of Alexion Pharmaceuticals by 8.2% in the first quarter. Candriam Luxembourg S.C.A. now owns 209,397 shares of the biopharmaceutical company’s stock valued at $25,388,000 after buying an additional 15,797 shares in the last quarter. Covenant Asset Management LLC raised its position in shares of Alexion Pharmaceuticals by 4.3% in the first quarter. Covenant Asset Management LLC now owns 17,834 shares of the biopharmaceutical company’s stock valued at $2,162,000 after buying an additional 734 shares in the last quarter. Oakbrook Investments LLC raised its position in shares of Alexion Pharmaceuticals by 81.5% in the first quarter. Oakbrook Investments LLC now owns 18,375 shares of the biopharmaceutical company’s stock valued at $2,228,000 after buying an additional 8,250 shares in the last quarter. Columbus Circle Investors raised its position in shares of Alexion Pharmaceuticals by 21.1% in the first quarter. Columbus Circle Investors now owns 75,796 shares of the biopharmaceutical company’s stock valued at $9,190,000 after buying an additional 13,183 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in shares of Alexion Pharmaceuticals by 40.7% in the first quarter. Nisa Investment Advisors LLC now owns 54,205 shares of the biopharmaceutical company’s stock valued at $6,572,000 after buying an additional 15,670 shares in the last quarter. Hedge funds and other institutional investors own 95.14% of the company’s stock.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 136.85 on Thursday. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $145.42. The company’s 50 day moving average is $128.92 and its 200-day moving average is $122.85. The firm has a market cap of $30.54 billion, a P/E ratio of 59.35 and a beta of 1.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912 million for the quarter, compared to the consensus estimate of $846.15 million. During the same quarter in the previous year, the firm posted $1.13 EPS. The firm’s quarterly revenue was up 21.1% on a year-over-year basis. Equities analysts expect that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Position Boosted by Cigna Investments Inc. New” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/alexion-pharmaceuticals-inc-alxn-position-boosted-by-cigna-investments-inc-new/1469353.html.

Several equities analysts recently weighed in on the company. BMO Capital Markets restated an “outperform” rating and issued a $168.00 price target (up previously from $159.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Leerink Swann lifted their price target on Alexion Pharmaceuticals from $136.00 to $170.00 and gave the company an “outperform” rating in a research note on Friday, July 28th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price target for the company in a research note on Wednesday, August 2nd. BidaskClub upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Finally, Oppenheimer Holdings, Inc. upgraded Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 price objective on the stock in a report on Friday, July 28th. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $156.89.

In other news, Director Bros. Advisors Lp Baker purchased 1,348,955 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were purchased at an average price of $116.32 per share, with a total value of $156,910,445.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Ludwig Hantson purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were purchased at an average cost of $116.72 per share, for a total transaction of $1,167,200.00. Following the purchase, the chief executive officer now directly owns 38,725 shares in the company, valued at $4,519,982. The disclosure for this purchase can be found here. Insiders have purchased a total of 2,019,734 shares of company stock worth $235,606,846 in the last ninety days. 4.35% of the stock is currently owned by insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.